Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 6/20 | 0.46 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.42 |
| ▸ | CHRNA7 | P36544 | 6/20 | 0.42 |
| ▸ | RXRA | P19793 | 1/20 | 0.37 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.37 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.37 |
| ▸ | JAK2 | O60674 | 1/20 | 0.37 |
| ▸ | JAK1 | P23458 | 1/20 | 0.37 |
| ▸ | JAK3 | P52333 | 1/20 | 0.37 |
| ▸ | PARP1 | P09874 | 1/20 | 0.37 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14923977 | 0.81 | KCNH2 (0.52) | KCNH2CHRNA7HRH4 | |
| SCHEMBL13317189 | 0.79 | PIK3CD (0.48) | KCNH2CHRNA7 | |
| SCHEMBL19381894 | 0.77 | CHRNA7 (0.58) | KCNH2CHRNA7PARP1 | |
| SCHEMBL26235665 | 0.77 | CHRNA7 (0.58) | KCNH2CHRNA7PARP1 | |
| SCHEMBL26498531 | 0.77 | NOTUM (0.51) | KCNH2NOTUMRXRAGRIN1GRIN2B | |
| SCHEMBL12461087 | 0.75 | PIK3CD (0.54) | KCNH2NOTUMCHRNA7 | |
| SCHEMBL25556995 | 0.73 | KCNH2 (0.43) | KCNH2CHRNA7JAK1 | |
| SCHEMBL25556993 | 0.72 | KCNH2 (0.40) | KCNH2CHRNA7JAK1JAK3 | |
| SCHEMBL25557074 | 0.72 | KCNH2 (0.40) | KCNH2CHRNA7JAK1JAK3 | |
| SCHEMBL21641736 | 0.71 | KCNH2 (0.44) | KCNH2CHRNA7PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230322789-A1 | PYRAZOLOPYRIDAZINONE COMPOUND, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | BROADENBIO CO., LTD. (CN) | 2023-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230322789-A1 | PYRAZOLOPYRIDAZINONE COMPOUND, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | PDXK, CMPK1, GCK | KCNH2 539/4885NOTUM 1891/4885CHRNA7 1772/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.